Abstract Library

#4257 Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

Introduction: The addition of stereotactic body radiation therapy (SBRT) to patients treated with PRRT may provide synergistic benefit by targeting specific sites of disease that represent areas of tumor heterogeneity. Little is known regarding the efficacy or potential toxicity of this approach. A retrospective review of patients with NEN treated with sequential PRRT and SBRT was performed to provide preliminary outcome and toxicity data to inform further combined treatment strategies.

Conference:

Presenting Author: Myrehaug S

Authors: Nunez Rodriguez J, Ng S, Chen H, Singh S, Hallet J,

Keywords: PRRT, Radiation, SABR, SBRT,

#4155 [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomised NETTER-2 study

Introduction: There is no universally accepted first line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference:

Presenting Author: de Herder W

Authors: de Herder W, Halperin D, Myrehaug S, Herrmann K, Pavel M,

Keywords: [177Lu]Lu-DOTA-TATE, Lutathera, Gastroenteropancreatic Neuroendocrine Tumor, NETTER-2,

#3175 Secondary primary cancers and survival among neuroendocrine tumor patients

Introduction: Higher rates of second cancer (SC) are suggested for patients with neuroendocrine tumors (NET), but data on SC are scare and their impact on outcomes is unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bateni S

Authors: Bateni S, Coburn N, Law C, Singh S, Myrehaug S,

Keywords: neuroendocrine tumor, secondary cancers, survival, gastrointestinal neuroendocrine tumor, pancreatic neuroendocrine tumor, pulmonary neuroendocrine tumor,

#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs

Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Lagler H, Mazal P, Kretschmer-Chott E, Haug A,

Keywords: pancreatic neuroendocrine tumors, treatment, somatostatin analogs, antibiotics, lanreotide,

#2097 Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues

Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Duan H, Haug A, Riss P, Selberherr A,

Keywords: carcinoid syndrome, ondansetron, 5-HT3 antagonist, neuroendocrine tumor, somatostatin, analogues,